Active Substance: Solifenacin succinate.
Overview
Welcome to Dwaey, specifically on URINACIN 10mg page.
This medicine contains an important and useful components, as it consists of
Solifenacin succinateis available in the market in concentration
Solifenacin Succinate
Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation.
Overactive bladder
Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention.
Constipation, dyspepsia, nausea, upper abdominal pain, xerostomia, hypertension, oedema, headache, depression, fatigue, urinary tract infection, blurred vision, cough, influenza.
3
Solifenacin is a selective M3 antimuscarinic that inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume and decreased detrusor muscle pressure.
May interfere with the prokinetic effects of cisapride and metoclopramide. Potentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. Strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.
Information not available